|
Table 1. Susceptibility pattern of E. coli against antibiotics according to patient age group. |
||||||||||||
|
Antibiotics |
Pattern |
Age of the patients |
Total % (n) |
|||||||||
|
1-10 |
11-20 |
21-30 |
31-40 |
41-50 |
51-60 |
61-70 |
71-80 |
81-90 |
|
|
||
|
Amoxycillin (20 μg) |
S |
0.0(0) |
12.5(6) |
31.3(15) |
12.5(6) |
6.3(3) |
18.8(9) |
18.8(9) |
0.0(0) |
0.0(0) |
100(48) |
|
|
R |
5.9(24) |
4.4(18) |
13.3(54) |
14.1(57) |
25.2(102) |
14.1(57) |
12.6(51) |
6.7(27) |
3.7(15) |
100(405) |
|
|
|
Cephradine (30 μg) |
S |
2.4(3) |
4.8(6) |
31.0(39) |
16.7(21) |
14.3(18) |
9.5(12) |
19.0(24) |
2.4(3) |
0.0(0) |
100(126) |
|
|
I |
0.0(0) |
0.0(0) |
0.0(0) |
50.0(6) |
25.0(3) |
25.0(3) |
0.0(0) |
0.0(0) |
0.0(0) |
100(12) |
|
|
|
R |
6.7(21) |
5.7(18) |
9.5(30) |
11.4(36) |
26.7(84) |
16.2(51) |
11.4(36) |
7.6(24) |
4.8(15) |
100(315) |
|
|
|
Ceftriaxone (30 μg) |
S |
3.4(6) |
5.2(9) |
24.1(42) |
15.5(27) |
17.2(30) |
15.5(27) |
15.5(27) |
3.4(6) |
0.0(0) |
100(174) |
|
|
I |
0.0(0) |
0.0(0) |
0.0(0) |
0.0(0) |
100(3) |
0.0(0) |
0.0(0) |
0.0(0) |
0.0(0) |
100(3) |
|
|
|
R |
6.5(18) |
5.4(15) |
9.8(27) |
13.0(36) |
26.1(72) |
14.1(39) |
12.0(33) |
7.6(21) |
5.4(15) |
100(276) |
|
|
|
Ceftazidime (30 μg) |
S |
8.5(18) |
2.8(6) |
18.3(39) |
16.9(36) |
25.4(54) |
14.1(30) |
9.9(21) |
4.2(9) |
0.0(0) |
100(213) |
|
|
I |
10.0(3) |
0.0(0) |
10.0(3) |
20.0(6) |
10.0(3) |
10.0(3) |
10.0(3) |
20.0(6) |
10.0(3) |
100(30) |
|
|
|
R |
1.4(3) |
8.6(18) |
12.9(27) |
10.0(21) |
22.9(48) |
15.7(33) |
17.1(36) |
5.7(12) |
5.7(12) |
100(210) |
|
|
|
Imipenem (10 μg) |
S |
5.8(24) |
4.3(18) |
14.5(60) |
13.8(57) |
24.6(102) |
15.2(63) |
13.0(54) |
5.8(24) |
2.9(12) |
100(414) |
|
|
I |
0.0(0) |
0.0(0) |
0.0(0) |
0.0(0) |
0.0(0) |
0.0(0) |
50.0(3) |
50.0(3) |
0.0(0) |
100(6) |
|
|
|
R |
0.0(0) |
18.2(6) |
27.3(9) |
18.2(6) |
9.1(3) |
9.1(3) |
9.1(3) |
0.0(0) |
9.1(3) |
100(33) |
|
|
|
Erythromycin (15 μg) |
S |
0.0(0) |
33.3(3) |
0.0(0) |
0.0(0) |
33.3(3) |
0.0(0) |
33.3(3) |
0.0(0) |
0.0(0) |
100(9) |
|
|
R |
5.4(24) |
4.7(21) |
15.5(69) |
14.2(63) |
23.0(102) |
14.9(66) |
12.8(57) |
6.1(27) |
3.4(15) |
100(444) |
|
|
|
Co_trimoxazole (25 μg) |
S |
3.1(3) |
9.4(9) |
21.9(21) |
15.6(15) |
21.9(21) |
9.4(9) |
12.5(12) |
6.3(6) |
0.0(0) |
100(96) |
|
|
I |
0.0(0) |
0.0(0) |
0.0(0) |
0.0(0) |
100.0(3) |
0.0(0) |
0.0(0) |
0.0(0) |
0.0(0) |
100(3) |
|
|
|
R |
5.9(21) |
4.2(15) |
13.6(48) |
13.6(48) |
22.9(81) |
16.1(57) |
13.6(48) |
5.9(21) |
4.2(15) |
100(354) |
|
|
|
Moxifloxacin (5 μg) |
S |
3.9(6) |
2.0(3) |
23.5(36) |
17.6(27) |
25.5(39) |
7.8(12) |
17.6(27) |
2.0(3) |
0.0(0) |
100(153) |
|
|
I |
12.5(6) |
0.0(0) |
12.5(6) |
18.8(9) |
6.3(3) |
18.8(9) |
6.3(3) |
12.5(6) |
12.5(6) |
100(48) |
|
|
|
R |
4.8(12) |
8.3(21) |
10.7(27) |
10.7(27) |
25.0(63) |
17.9(45) |
11.9(30) |
7.1(18) |
3.6(9) |
100(252) |
|
|
|
Gentamicin (10 μg) |
S |
6.7(18) |
4.4(12) |
15.6(42) |
16.7(45) |
24.4(66) |
12.2(33) |
13.3(36) |
5.6(15) |
1.1(3) |
100(270) |
|
|
I |
5.6(3) |
5.6(3) |
22.2(12) |
11.1(6) |
22.2(12) |
16.7(9) |
11.1(6) |
0.0(0) |
5.6(3) |
100(54) |
|
|
|
R |
2.3(3) |
7.0(9) |
11.6(15) |
9.3(12) |
20.9(27) |
18.6(24) |
14.0(18) |
9.3(12) |
7.0(9) |
100(129) |
|
|
|
Netilmycin (30 μg) |
S |
5.6(18) |
2.8(9) |
13.1(42) |
15.9(51) |
27.1(87) |
14.0(45) |
12.1(39) |
5.6(18) |
3.7(12) |
100(321) |
|
|
I |
7.7(3) |
23.1(9) |
15.4(6) |
7.7(3) |
7.7(3) |
15.4(6) |
15.4(6) |
0.0(0) |
7.7(3) |
100(39) |
|
|
|
R |
3.2(3) |
6.5(6) |
22.6(21) |
9.7(9) |
16.1(15) |
16.1(15) |
16.1(15) |
9.7(9) |
0.0(0) |
100(93) |
|
|
|
Nalidixic_Acid (30 μg) |
S |
10.0(9) |
6.7(6) |
26.7(24) |
13.3(12) |
10.0(9) |
13.3(12) |
13.3(12) |
6.7(6) |
0.0(0) |
100(90) |
|
|
I |
0.0(0) |
0.0(0) |
0.0(0) |
0.0(0) |
0.0(0) |
100.0(3) |
0.0(0) |
0.0(0) |
0.0(0) |
100(3) |
|
|
|
R |
4.2(15) |
5.0(18) |
12.5(45) |
14.2(51) |
26.7(96) |
14.2(51) |
13.3(48) |
5.8(21) |
4.2(15) |
100(360) |
|
|
|
Ciprofloxacin (5 μg) |
S |
5.6(9) |
1.9(3) |
24.1(39) |
18.5(30) |
18.5(30) |
13.0(21) |
14.8(24) |
3.7(6) |
0.0(0) |
100(162) |
|
|
I |
14.3(3) |
0.0(0) |
14.3(3) |
14.3(3) |
14.3(3) |
28.6(6) |
0.0(0) |
0.0(00 |
14.3(3) |
100(21) |
|
|
|
R |
4.4(12) |
7.8(21) |
10(27) |
11.1(30) |
26.7(72) |
14.4(39) |
13.3(36) |
7.8(21) |
4.4(12) |
100(270) |
|
|
|
Levofloxacin (5 μg) |
S |
5.2(9) |
1.7(3) |
24.1(42) |
17.2(30) |
20.7(36) |
13.8(24) |
13.8(24) |
3.4(6) |
0.0(0) |
100(174) |
|
|
I |
18.2(6) |
0.0(0) |
9.1(3) |
9.1(3) |
9.1(3) |
18.2(6) |
18.2(6) |
9.1(3) |
9.1(3) |
100(33) |
|
|
|
R |
3.7(9) |
8.5(21) |
9.8(24) |
12.2(30) |
26.8(66) |
14.6(36) |
12.2(30) |
7.3(18) |
4.9(12) |
100(246) |
|
|
|
Nitrofurantoin (300 μg) |
S |
5.6(21) |
5.6(21) |
13.6(51) |
13.6(51) |
24.8(93) |
14.4(54) |
12.8(48) |
6.4(24) |
3.2(12) |
100(375) |
|
|
I |
0.0(0) |
0.0(0) |
0.0(0) |
0.0(0) |
0.0(0) |
50.0(3) |
50.0(3) |
0.0(0) |
0.0(0) |
100(6) |
|
|
|
R |
4.2(3) |
4.2(3) |
25.0(18) |
16.7(12) |
16.7(12) |
12.5(9) |
12.5(9) |
4.2(3) |
4.2(3) |
100(72) |
|
|
|
Amikacin (30 μg) |
S |
5.4(18) |
3.6(12) |
17.1(57) |
16.2(54) |
24.3(81) |
11.7(39) |
11.7(39) |
5.4(18) |
4.5(15) |
100(333) |
|
|
I |
8.3(3) |
8.3(3) |
8.3(3) |
8.3(3) |
8.3(3) |
16.7(6) |
25.0(9) |
16.7(6) |
0.0(0) |
100(84) |
|
|
|
R |
3.6(3) |
10.7(9) |
10.7(9) |
7.1(6) |
25.0(21) |
25.0(21) |
14.3(12) |
3.6(3) |
0.0(0) |
100(36) |
|
|
|
Aztreonam (30 μg) |
S |
6.3(9) |
4.2(6) |
22.9(33) |
16.7(24) |
25.0(36) |
10.4(15) |
4.2(6) |
6.3(9) |
4.2(6) |
100(144) |
|
|
I |
13.3(6) |
0.0(0) |
6.7(3) |
13.3(6) |
33.3(15) |
26.7(12) |
6.7(3) |
0.0(0) |
0.0(0) |
100(45) |
|
|
|
R |
3.4(9) |
6.8(18) |
12.5(33) |
12.5(33) |
20.5(54) |
14.8(39) |
19.3(51) |
6.8(18) |
3.4(9) |
100(264) |
|
|
|
(n)- indicates the number of patients, S=Sensitive, I=Intermediate, R= Resistant |
|
|||||||||||